相关实验视频

Updated: Jun 18, 2025

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

11.9K

奇格利塔扎尔通过调节小鼠的多个途径来减轻高脂肪饮食引起的非酒精性脂肪性肝病

Lijuan Liu1, Weiming Sun2, Xulei Tang1

  • 1Department of Endocrinology, The First Hospital of Lanzhou University, Lanzhou, 730000, Gansu, China; The First Clinical Medical College, Lanzhou University, Lanzhou, 730000, Gansu, China.

Molecular and cellular endocrinology
|August 4, 2024
PubMed
概括

奇格利塔扎尔是一种泛PPAR激动剂,在非酒精性脂肪性肝病 (NAFLD) 中显示出治疗潜力. 它改善了NAFLD小鼠的代谢健康,减少了肝脏脂肪,炎症和氧化应激.

关键词:
奇格利塔扎尔是什么意思 奇格利塔扎尔是什么意思非酒精性脂肪肝疾病是非酒精性脂肪肝疾病.这些是PPARs.进行RNA测序.

更多相关视频

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

15.9K
Body Composition and Metabolic Caging Analysis in High Fat Fed Mice10:28

Body Composition and Metabolic Caging Analysis in High Fat Fed Mice

Published on: May 24, 2018

15.5K

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
180
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
311